Cargando…
Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
BACKGROUND/AIMS: Second-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC) that progresses following gemcitabine-based treatment has not been established. This study aimed to investigate the efficacy and safety of second-line combination chemotherapy with capecitabin...
Autores principales: | Chung, Kwang Hyun, Ryu, Ji Kon, Son, Jun Hyuk, Lee, Jae Woo, Jang, Dong Kee, Lee, Sang Hyub, Kim, Yong-Tae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of Gut and Liver
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347656/ https://www.ncbi.nlm.nih.gov/pubmed/27965478 http://dx.doi.org/10.5009/gnl16307 |
Ejemplares similares
-
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022) -
A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
por: Woo, Sang Myung, et al.
Publicado: (2013) -
Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015) -
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017) -
Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)